Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, MC 0358, La Jolla, CA 92093-0358, USA.
Org Biomol Chem. 2010 Nov 21;8(22):5105-9. doi: 10.1039/c0ob00228c. Epub 2010 Sep 6.
This paper presents a pH-sensitive bifunctional crosslinker that enables facile conjugation of small molecule therapeutics to macromolecular carriers for use in drug delivery systems. This N-ethoxybenzylimidazole (NEBI) bifunctional crosslinker was designed to exploit mildly acidic, subcellular environments to trigger the release of therapeutics upon internalization in cells. We demonstrate that an analog of doxorubicin (a representative example of an anticancer therapeutic) conjugated to human serum albumin (HSA, a representative example of a macromolecular carrier) via this NEBI crosslinker can internalize and localize into acidic lysosomes of ovarian cancer cells. Fluorescence imaging and cell viability studies demonstrate that the HSA-NEBI-doxorubicin conjugate exhibited improved uptake and cytotoxic activity compared to the unconjugated doxorubicin analog. The pH-sensitive NEBI group was also shown to be relatively stable to biologically-relevant metal Lewis acids and to serum proteins, supporting that these bifunctional crosslinkers may be useful for constructing drug delivery systems that will be stable in biological fluids such as blood.
本文提出了一种 pH 敏感的双功能交联剂,可方便地将小分子治疗药物与大分子载体连接,用于药物传递系统。这种 N-乙氧基苄基咪唑(NEBI)双功能交联剂的设计利用了轻度酸性的亚细胞环境,在细胞内化时触发治疗药物的释放。我们证明,通过这种 NEBI 交联剂连接到人血清白蛋白(HSA,大分子载体的代表)的阿霉素类似物(抗癌治疗的代表例子)可以内化并定位于卵巢癌细胞的酸性溶酶体中。荧光成像和细胞活力研究表明,与未共轭的阿霉素类似物相比,HSA-NEBI-阿霉素缀合物的摄取和细胞毒性活性得到了改善。还表明,pH 敏感的 NEBI 基团对生物相关的金属路易斯酸和血清蛋白相对稳定,支持这些双功能交联剂可用于构建在血液等生物流体中稳定的药物传递系统。